Oculis Holding AG Ordinary shares (OCS) News
Latest headlines that mention OCS, newest first · each headline opens the original publisher
- Last price
- $7.44
- Day change
- +0.68%
- Next earnings
- —
OCS headlines
latest coverageOculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
OCS news alerts
Get an alert by email or push when a new headline mentions OCS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.